![](https://www.diabetesnews.com/wp-content/uploads/2013/12/Metformin_500mg_TabletsUse-150x150.jpg)
The FDA recently released a Drug Safety Communication announcing revisions to metformin’s label to expand use in people with type 2 diabetes and mild to moderate kidney (renal) impairment. Previously, the FDA advised against using metformin (Glucophage, Glumetza, Riomet, and Fortamet) in this group.